Home › Compare › HMCTF vs ABBV
HMCTF yields 165.29% · ABBV yields 3.06%● Live data
📍 HMCTF pulled ahead of the other in Year 1
Combined, HMCTF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of HMCTF + ABBV for your $10,000?
Hainan Meilan International Airport Company Limited, together with its subsidiaries, engages in the aeronautical and non-aeronautical businesses at the Haikou Meilan International Airport in Haikou, the People's Republic of China. Its aeronautical business includes the provision of terminal facilities, ground handling services, and passenger services. The company's non-aeronautical business comprises the leasing of commercial and retail spaces at Haikou Meilan International Airport; franchise of airport-related business; leasing of advertising space; provision of car parking and cargo handling services; and sale of consumable goods. It is also involved in the business investment, and hotel investment and operation activities; and rendering of cargo and logistics services. The company was formerly known as Regal International Airport Group Company Limited and changed its name to Hainan Meilan International Airport Company Limited in November 2019. The company was incorporated in 2000 and is headquartered in Haikou, the People's Republic of China. Hainan Meilan International Airport Company Limited is a subsidiary of Haikou Meilan International Airport Company Limited.
Full HMCTF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.